Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04699838Phase 2Recruiting

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Role: lead

NCT02769832Phase 2Completed

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Role: lead

NCT03951012Terminated

Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy

Role: lead

NCT03982134Phase 1Withdrawn

PDR001 + Panobinostat for Melanoma and NSCLC

Role: lead

All 4 trials loaded